News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
Zoetis (ZTS) Joint Venture in China Receives Approval for Rui Lan An Swine Vaccine Against PRRS
8/5/2013 6:53:35 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Zoetis Joint Venture in China Receives Approval for Rui Lan An™ Swine Vaccine Against PRRS
HUINAN, JILIN, China--(BUSINESS WIRE)-- Zoetis today announced that its joint venture in China received the approval by the Ministry of Agriculture of the People’s Republic of China for Rui Lan An™, a specialized vaccine to help control the highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS). Rui Lan An, which will be launched later this month, is the first vaccine to emerge from the joint venture that was established to develop and manufacture animal vaccines specifically designed to answer the needs of China’s livestock producers. It will help China’s pork producers meet increasing demand in China for quality, affordable pork.
“Our innovation starts with our customers and an understanding of their everyday animal health challenges. Rui Lan An exemplifies the commitment of our joint venture to develop and manufacture quality vaccines well matched to the local health challenges facing China’s pork industry,” said Stefan Weiskopf, Executive Vice President and President, Asia Pacific Region at Zoetis. “The vaccine represents our commitment to help assure a safe, sustainable food supply from healthy food production animals through global scientific expertise and local innovation. It is a key milestone for Zoetis’ business in China.”
Vaccines for swine have high growth potential as China is the world’s leading pork producing nation, with an annual population of more than 685 million pigs in 2012. The joint venture provides a strategic platform for growth in China where the animal health industry is valued at $1.8 billion and is expected to grow at 9.3 percent year over year in the next 5 years.1
Zoetis (zo-EH-tis) is the leading global animal health company, dedicated to supporting customers and businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, with a focus on both farm and companion animals. In 2012, the company generated annual revenues of $4.3 billion. With approximately 9,300 employees worldwide and a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for livestock and companion animals in 120 countries. For more information, visit www.zoetis.com.
Forward-Looking Statements: This news release contains forward-looking statements, which reflect Zoetis’ current views with respect to business plans or prospects, future operating or financial performance, and other future events. These statements are not guarantees of future performance. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, including in the sections thereof captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors”, in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
Internet Posting of Information: We routinely post information that may be important to investors in the ‘Investors’ section of our web site at www.zoetis.com, on our Facebook page at http://www.facebook.com/zoetis and on Twitter @zoetis. We encourage investors and potential investors to consult our web site regularly and to follow us on Facebook and Twitter for important information about us.
1 Vetnosis STORM 2013
Priya Chandramohan, +65 69335965
Elinore White, 973-443-2835
Help employers find you! Check out all the jobs and post your resume.